Greg Matlashewski

List of Publications by Year
in descending order

109 papers	6,801 citations	81900 39 h-index	64796 79 g-index
118 all docs	118 docs citations	118 times ranked	6003 citing authors

#	Article	IF	Citations
1	Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer. Nature, 1998, 393, 229-234.	27.8	897
2	Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically. Molecular and Cellular Biology, 1999, 19, 1092-1100.	2.3	633
3	Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. FEBS Journal, 1986, 159, 529-534.	0.2	469
4	Immune Responses Induced by the Leishmania (Leishmania) donovani A2 Antigen, but Not by the LACK Antigen, Are Protective against Experimental Leishmania (Leishmania) amazonensis Infection. Infection and Immunity, 2003, 71, 3988-3994.	2.2	220
5	Regulation of Human p53 Activity and Cell Localization by Alternative Splicing. Molecular and Cellular Biology, 2004, 24, 7987-7997.	2.3	197
6	Determinants for the Development of Visceral Leishmaniasis Disease. PLoS Pathogens, 2013, 9, e1003053.	4.7	175
7	CRISPR-Cas9-Mediated Genome Editing in Leishmania donovani. MBio, 2015, 6, e00861.	4.1	168
8	Successful Treatment of Drugâ€Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator. Clinical Infectious Diseases, 2001, 33, 1847-1851.	5.8	158
9	Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and Sâ€²8463: Efficacy and Mode of Action. Journal of Infectious Diseases, 1999, 179, 1485-1494.	4.0	148
10	Analysis of human p53 proteins and mRNA levels in normal and transformed cells. FEBS Journal, 1986, 154, 665-672.	0.2	136
11	Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Molecular and Biochemical Parasitology, 1996, 78, 79-90.	1.1	130
12	The Developmental Expression of A2 Amastigote-specific Genes Is Post-transcriptionally Mediated and Involves Elements Located in the 3â€²-Untranslated Region. Journal of Biological Chemistry, 1996, 271, 17081-17090.	3.4	120
13	General Suppression of Macrophage Gene Expression DuringLeishmania donovaniInfection. Journal of Immunology, 2001, 166, 3416-3422.	0.8	120
14	Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Molecular Microbiology, 2001, 39, 935-948.	2.5	111
15	Visceral leishmaniasis: elimination with existing interventions. Lancet Infectious Diseases, The, 2011, 11, 322-325.	9.1	109
16	Comparison of the A2 Gene Locus in Leishmania donovani and Leishmania major and Its Control over Cutaneous Infection. Journal of Biological Chemistry, 2003, 278, 35508-35515.	3.4	99
17	Mobile suitcase laboratory for rapid detection of Leishmania donovani using recombinase polymerase amplification assay. Parasites and Vectors, 2016, 9, 281.	2.5	98
18	Genetic Analysis of Leishmania donovani Tropism Using a Naturally Attenuated Cutaneous Strain. PLoS Pathogens, 2014, 10, e1004244.	4.7	97

#	Article	IF	Citations
19	Immunization with a Toll-Like Receptor 7 and/or 8 Agonist Vaccine Adjuvant Increases Protective Immunity againstLeishmania majorin BALB/c Mice. Infection and Immunity, 2008, 76, 3777-3783.	2.2	94
20	Control of Î± Subunit of Eukaryotic Translation Initiation Factor 2 (eIF2Î±) Phosphorylation by the Human Papillomavirus Type 18 E6 Oncoprotein: Implications for eIF2Î±-Dependent Gene Expression and Cell Death. Molecular and Cellular Biology, 2004, 24, 3415-3429.	2.3	93
21	Role of Imiquimod and Parenteral Meglumine Antimoniate in the Initial Treatment of Cutaneous Leishmaniasis. Clinical Infectious Diseases, 2007, 44, 1549-1554.	5.8	91
22	Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagnostic Microbiology and Infectious Disease, 2002, 43, 289-295.	1.8	86
23	Comparison of the Effects ofLeishmania majororLeishmania donovaniInfection on Macrophage Gene Expression. Infection and Immunity, 2008, 76, 1186-1192.	2.2	81
24	Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 1999, 6, 223-233.	1.1	80
25	Transmission Dynamics of Visceral Leishmaniasis in the Indian Subcontinent â€“ A Systematic Literature Review. PLoS Neglected Tropical Diseases, 2016, 10, e0004896.	3.0	74
26	Atypical leishmaniasis: A global perspective with emphasis on the Indian subcontinent. PLoS Neglected Tropical Diseases, 2018, 12, e0006659.	3.0	74
27	A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nature Communications, 2020, 11, 3461.	12.8	72
28	Leishmania infection and virulence. Medical Microbiology and Immunology, 2001, 190, 37-42.	4.8	66
29	Optimized CRISPR-Cas9 Genome Editing for Leishmania and Its Use To Target a Multigene Family, Induce Chromosomal Translocation, and Study DNA Break Repair Mechanisms. MSphere, 2017, 2, .	2.9	66
30	First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent Antimony. PLoS Neglected Tropical Diseases, 2009, 3, e491.	3.0	65
31	Adjuvants for Leishmania vaccines: from models to clinical application. Frontiers in Immunology, 2012, 3, 144.	4.8	64
32	Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein. Molecular Microbiology, 2010, 77, 518-530.	2.5	60
33	Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. The Lancet Global Health, 2014, 2, e51-e57.	6.3	58
34	Towards elimination of visceral leishmaniasis in the Indian subcontinentâ€”Translating research to practice to public health. PLoS Neglected Tropical Diseases, 2017, 11, e0005889.	3.0	53
35	The expression of biologically active human p53 inLeishmaniacells: a novel eukaryotic system to produce recombinant proteins. Nucleic Acids Research, 1995, 23, 4073-4080.	14.5	47
36	Intracellular Eukaryotic Parasites Have a Distinct Unfolded Protein Response. PLoS ONE, 2011, 6, e19118.	2.5	45

#	Article	IF	Citations
37	Screening Leishmania donovaniâ€specific genes required for visceral infection. Molecular Microbiology, 2010, 77, 505-517.	2.5	42
38	Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and Ej-ras. International Journal of Cancer, 1988, 42, 232-238.	5.1	41
39	A complete Leishmania donovani reference genome identifies novel genetic variations associated with virulence. Scientific Reports, 2018, 8, 16549.	3.3	41
40	Leishmania donovanizymodeme MON-37 isolated from an autochthonous visceral leishmaniasis patient in Sri Lanka. Pathogens and Global Health, 2012, 106, 421-424.	2.3	40
41	Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. PLoS Neglected Tropical Diseases, 2016, 10, e0005196.	3.0	40
42	Identification and Characterization of a Protein-tyrosine Phosphatase in Leishmania. Journal of Biological Chemistry, 2006, 281, 36257-36268.	3.4	39
43	Research priorities for elimination of visceral leishmaniasis. The Lancet Global Health, 2014, 2, e683-e684.	6.3	36
44	Identification of Genes Induced by a Macrophage Activator, S-28463, Using Gene Expression Array Analysis. Antimicrobial Agents and Chemotherapy, 2001, 45, 1137-1142.	3.2	35
45	Development of a Genetic Assay to Distinguish between Leishmania viannia Species on the Basis of Isoenzyme Differences. Clinical Infectious Diseases, 2006, 42, 801-809.	5.8	34
46	Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in Leishmania. MSphere, 2019, 4, .	2.9	34
47	Involvement of Nuclear Export in Human Papillomavirus Type 18 E6-Mediated Ubiquitination and Degradation of p53. Journal of Virology, 2005, 79, 8773-8783.	3.4	33
48	Human Papillomavirus Type 33 Polymorphisms and Highâ€Grade Squamous Intraepithelial Lesions of the Uterine Cervix. Journal of Infectious Diseases, 2006, 194, 886-894.	4.0	33
49	Reducing Visceral Leishmaniasis by Insecticide Impregnation of Bed-Nets, Bangladesh. Emerging Infectious Diseases, 2013, 19, 1131-1134.	4.3	32
50	Characterization of a Î²-tubulin gene and Î²-tubulin gene products of Brugia pahangi. Molecular and Biochemical Parasitology, 1991, 44, 153-164.	1.1	31
51	A FRET-Based Real-Time PCR Assay to Identify the Main Causal Agents of New World Tegumentary Leishmaniasis. PLoS Neglected Tropical Diseases, 2013, 7, e1956.	3.0	31
52	Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Communications Biology, 2021, 4, 929.	4.4	30
53	Inducible Expression of Suicide Genes in Leishmania donovani Amastigotes. Journal of Biological Chemistry, 1998, 273, 22997-23003.	3.4	29
54	Involvement of the Leishmania donovani virulence factor A2 in protection against heat and oxidative stress. Experimental Parasitology, 2012, 132, 109-115.	1.2	29

#	Article	IF	Citations
55	Asymptomatic Leishmania infections in northern India: a threat for the elimination programme?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 679-684.	1.8	29
56	Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. Journal of Medical Microbiology, 2011, 60, 1248-1260.	1.8	28
57	Development of Leishmania vaccines in the era of visceral leishmaniasis elimination. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 423-424.	1.8	28
58	Characterization of a new Leishmania major strain for use in a controlled human infection model. Nature Communications, 2021, 12, 215.	12.8	28
59	Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. Journal of General Virology, 2004, 85, 1419-1426.	2.9	27
60	Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent. PLoS Neglected Tropical Diseases, 2017, 11, e0005190.	3.0	26
61	Leishmania donovani hybridisation and introgression in nature: a comparative genomic investigation. Lancet Microbe, The, 2021, 2, e250-e258.	7.3	26
62	Analysis of antisense and double stranded RNA downregulation of A2 protein expression in Leishmania donovani. Molecular and Biochemical Parasitology, 2000, 107, 315-319.	1.1	25
63	Diagnosis of Visceral Leishmaniasis in Bihar India: Comparison of the rK39 Rapid Diagnostic Test on Whole Blood Versus Serum. PLoS Neglected Tropical Diseases, 2013, 7, e2233.	3.0	25
64	A Genomic-Based Approach Combining In Vivo Selection in Mice to Identify a Novel Virulence Gene in Leishmania. PLoS Neglected Tropical Diseases, 2008, 2, e248.	3.0	25
65	Leishmania donovani infection enhances macrophage viability in the absence of exogenous growth factor. Journal of Leukocyte Biology, 1994, 55, 91-98.	3.3	24
66	Revival of Leishmanization and Leishmanin. Frontiers in Cellular and Infection Microbiology, 2021, 11, 639801.	3.9	22
67	A review of the leishmanin skin test: A neglected test for a neglected disease. PLoS Neglected Tropical Diseases, 2021, 15, e0009531.	3.0	22
68	Role of Cytosolic Glyceraldehyde-3-Phosphate Dehydrogenase in Visceral Organ Infection by Leishmania donovani. Eukaryotic Cell, 2013, 12, 70-77.	3.4	21
69	Cross-Sectional Study to Assess Risk Factors for Leishmaniasis in an Endemic Region in Sri Lanka. American Journal of Tropical Medicine and Hygiene, 2013, 89, 742-749.	1.4	21
70	Efficacy, Safety and Cost of Insecticide Treated Wall Lining, Insecticide Treated Bed Nets and Indoor Wall Wash with Lime for Visceral Leishmaniasis Vector Control in the Indian Sub-continent: A Multi-country Cluster Randomized Controlled Trial. PLoS Neglected Tropical Diseases, 2016, 10, e0004932.	3.0	21
71	Adaptation of Leishmania donovani to Cutaneous and Visceral Environments: in Vivo Selection and Proteomic Analysis. Journal of Proteome Research, 2015, 14, 1033-1059.	3.7	20
72	Integrating Case Detection of Visceral Leishmaniasis and Other Febrile Illness with Vector Control in the Post-Elimination Phase in Nepal. American Journal of Tropical Medicine and Hygiene, 2019, 100, 108-114.	1.4	19

#	Article	IF	Citations
73	Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis. Npj Vaccines, 2022, 7, 32.	6.0	19
74	Application of CRISPR/Cas9-Mediated Genome Editing in Leishmania. Methods in Molecular Biology, 2020, 2116, 199-224.	0.9	18
75	Clearance of Infection with Mycobacterium bovis BCG in Mice Is Enhanced by Treatment with S28463 (R-848), and Its Efficiency Depends on Expression of Wild-Type Nramp1 (Resistance Allele). Antimicrobial Agents and Chemotherapy, 2001, 45, 3059-3064.	3.2	17
76	Sensing Host Arginine Is Essential for Leishmania Parasitesâ€™ Intracellular Development. MBio, 2020, 11, .	4.1	17
77	Identification of a novel Brugia pahangi Î²-tubulin gene (Î²2) and a 22-nucleotide spliced leader sequence on Î²1-tubulin mRNA. Molecular and Biochemical Parasitology, 1992, 50, 275-284.	1.1	16
78	Heterologous expression of a mammalian protein tyrosine phosphatase gene in Leishmania: effect on differentiation. Molecular Microbiology, 2003, 50, 1517-1526.	2.5	16
79	Impact of ASHA Training on Active Case Detection of Visceral Leishmaniasis in Bihar, India. PLoS Neglected Tropical Diseases, 2014, 8, e2774.	3.0	16
80	Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients. BMC Infectious Diseases, 2018, 18, 500.	2.9	16
81	Evaluation of Real-time PCR for Diagnosis of Post-Kala-azar Dermal Leishmaniasis in Endemic Foci of Bangladesh. Open Forum Infectious Diseases, 2018, 5, ofy234.	0.9	16
82	A2rel: a constitutively expressed Leishmania gene linked to an amastigote-stage-specific gene1Note: The sequence is also available on GenBankâ„¢, accession number AF016403.1. Molecular and Biochemical Parasitology, 1998, 93, 23-29.	1.1	15
83	Expression of a Leishmania donovani nucleotide sugar transporter in Leishmania major enhances survival in visceral organs. Experimental Parasitology, 2011, 129, 337-345.	1.2	15
84	In vivo selection for Leishmania donovani miniexon genes that increase virulence in Leishmania majorâ€. Molecular Microbiology, 2004, 54, 1051-1062.	2.5	14
85	Viral load of episomal and integrated forms of human papillomavirus type 33 in highâ€grade squamous intraepithelial lesions of the uterine cervix. International Journal of Cancer, 2007, 121, 2674-2681.	5.1	14
86	An intraspecies Leishmania donovani hybrid from the Indian subcontinent is associated with an atypical phenotype of cutaneous disease. IScience, 2022, 25, 103802.	4.1	12
87	Entomological efficacy of durable wall lining with reduced wall surface coverage for strengthening visceral leishmaniasis vector control in Bangladesh, India and Nepal. BMC Infectious Diseases, 2016, 16, 539.	2.9	11
88	Evidence that a naturally occurring single nucleotide polymorphism in the RagC gene of Leishmania donovani contributes to reduced virulence. PLoS Neglected Tropical Diseases, 2021, 15, e0009079.	3.0	11
89	A2 and Other Visceralizing Proteins of Leishmania: Role in Pathogenesis and Application for Vaccine Development. Sub-Cellular Biochemistry, 2014, 74, 77-101.	2.4	11
90	Molecular analysis of different allelic variants of wild-type human p53. Biochemistry and Cell Biology, 1992, 70, 1014-1019.	2.0	10

#	Article	IF	Citations
91	Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse. Frontiers in Microbiology, 2019, 10, 2268.	3.5	10
92	p53 polymorphism and risk of cervical cancer. Nature, 1998, 396, 532-532.	27.8	9
93	Detection of iNOS gene expression in cutaneous leishmaniasis biopsy tissue. Molecular and Biochemical Parasitology, 2002, 121, 145-147.	1.1	9
94	Barriers of Visceral Leishmaniasis reporting and surveillance in Nepal: comparison of governmental <scp>VL</scp>â€program districts with nonâ€program districts. Tropical Medicine and International Health, 2019, 24, 192-204.	2.3	9
95	p53: Twenty years on, Meeting Review. Oncogene, 1999, 18, 7618-7620.	5.9	8
96	Deletion of an ATP-binding cassette protein subfamily C transporter in Leishmania donovani results in increased virulence. Molecular and Biochemical Parasitology, 2012, 185, 165-169.	1.1	8
97	Intervention Packages for Early Visceral Leishmaniasis Case Detection and Sandfly Control in Bangladesh: A Comparative Analysis. American Journal of Tropical Medicine and Hygiene, 2019, 100, 97-107.	1.4	7
98	Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections. Journal of Clinical Microbiology, 2022, 60, JCM0171721.	3.9	7
99	Leishmania Major Centrin Gene-Deleted Parasites Generate Skin Resident Memory T-Cell Immune Response Analogous to Leishmanization. Frontiers in Immunology, 2022, 13, 864031.	4.8	7
100	Repeated training of accredited social health activists (ASHAs) for improved detection of visceral leishmaniasis cases in Bihar, India. Pathogens and Global Health, 2016, 110, 33-35.	2.3	6
101	Accelerated Active Case Detection of Visceral Leishmaniasis Patients in Endemic Villages of Bangladesh. PLoS ONE, 2014, 9, e103678.	2.5	5
102	One More Death from Visceral Leishmaniasis Has Gone by Unnoticed. What Can Be Done?. PLoS Neglected Tropical Diseases, 2013, 7, e2082.	3.0	4
103	Screening Leishmania donovani Complex-Specific Genes Required for Visceral Disease. Methods in Molecular Biology, 2015, 1201, 339-361.	0.9	4
104	Reconstitution of Mycobacterium marinum Nonhomologous DNA End Joining Pathway in Leishmania. MSphere, 2022, 7, .	2.9	4
105	The Phosphoenolpyruvate Carboxykinase Is a Key Metabolic Enzyme and Critical Virulence Factor of Leishmania major. Journal of Immunology, 2021, 206, 1013-1026.	0.8	3
106	Comparison of Novel Sandfly Control Interventions: A Pilot Study in Bangladesh. American Journal of Tropical Medicine and Hygiene, 2021, 105, 1786-1794.	1.4	3
107	Seropositivity of Visceral leishmaniasis on people of VL endemic three districts of Nepal. Parasitology International, 2021, 80, 102236.	1.3	2
108	Response to Visceral Leishmaniasis Cases through Active Case Detection and Vector Control in Low-Endemic Hilly Districts of Nepal. American Journal of Tropical Medicine and Hygiene, 2022, 107, 349-354.	1.4	2

#	Article	IF	Citations
109	The use of monoclonal antibodies for selection of a low-abundance mRNA: p53. Biochemical Society Transactions, 1984, 12, 708-711.	3.4	1